The Paris, France-based drugmaker’s shares rose by 2.9 percent in Paris Nov. 22 following the news, making it the biggest intraday gain for the drugmaker in four months.
A deal is not certain, but Sanofi CEO Paul Hudson will give a strategy update Dec. 10, according to Bloomberg.
Sanofi’s consumer health unit generated more than $5 billion in revenue last year. Selling the unit would send a positive signal about Sanofi’s ability to create new prescription drugs, Daniel Mahony, PhD, a healthcare fund manager told Bloomberg.
Read the full article here.
More articles on pharmacy:
AHA, CVS Health backed secretive anti-pharma group
EpiPen, Humira among drugs Warren wants to regulate
31 drugmakers at high risk for bankruptcy in 2020
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.